WARRANT AGREEMENTWarrant Agreement • March 31st, 2003 • Immune Response Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 31st, 2003 Company Industry JurisdictionWARRANT AGREEMENT (this “Agreement”), dated as of December 10, 2002, by and between The Immune Response Corporation, a Delaware corporation (the “Company”), and Cheshire Associates LLC, a Delaware limited liability company (the “Warrant Holder”).
WARRANT AGREEMENTWarrant Agreement • March 31st, 2003 • Immune Response Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 31st, 2003 Company Industry JurisdictionWARRANT AGREEMENT (this “Agreement”), dated as of November 20, 2002, by and between The Immune Response Corporation, a Delaware corporation (the “Company”), and Cheshire Associates LLC, a Delaware limited liability company (the “Warrant Holder”).
WARRANT AGREEMENTWarrant Agreement • March 31st, 2003 • Immune Response Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 31st, 2003 Company Industry JurisdictionWARRANT AGREEMENT (this “Agreement”), dated as of November 20, 2002, by and between The Immune Response Corporation, a Delaware corporation (the “Company”), and Cheshire Associates LLC, a Delaware limited liability company (the “Warrant Holder”).
WARRANT AGREEMENTWarrant Agreement • March 31st, 2003 • Immune Response Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 31st, 2003 Company Industry JurisdictionWARRANT AGREEMENT (this “Agreement”), dated as of November 27, 2002, by and between The Immune Response Corporation, a Delaware corporation (the “Company”), and Cheshire Associates LLC, a Delaware limited liability company (the “Warrant Holder”).
WARRANT AGREEMENTWarrant Agreement • May 20th, 2002 • Immune Response Corp • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 20th, 2002 Company Industry JurisdictionWARRANT AGREEMENT (this “Agreement”), dated as of May 3, 2002, by and between The Immune Response Corporation, a Delaware corporation (the “Company”), and Oshkim Limited Partnership, a Delaware limited partnership (the “Warrant Holder”).